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ABSTRACT
The treatment of peritoneal surface malignances has changed considerably 
over the last thirty years. Unfortunately, the palliative is the only current treatment 
for peritoneal carcinomatosis (PC). Two primary intraperitoneal chemotherapeutic 
methods are used. The first is combination of cytoreductive surgery (CRS) and 
Hyperthermic IntraPEritoneal Chemotherapy (HIPEC), which has become the gold 
standard for many cases of PC. The second is Pressurized IntraPeritoneal Aerosol 
Chemotheprapy (PIPAC), which is promising direction to minimally invasive as 
safedrug delivery. These methods were improved through multicenter studies and 
clinical trials that yield important insights and solutions. Major method development 
has been made through nanomedicine, specifically nanoparticles. Here, we are 
presenting the latest advances of nanoparticles and their application to precision 
diagnostics and improved treatment strategies for PC. These advances will likely 
develop both HIPEC and PIPAC methods that used for in vitro and in vivo studies. 
Several benefits of using nanoparticles will be discussed including: 1) Nanoparticles 
as drug delivery systems; 2) Nanoparticles and Near Infrred (NIR) Irradiation; 3) use 
of nanoparticles in perioperative diagnostic and individualized treatment planning; 
4) use of nanoparticles as anticancer dressing’s, hydrogels and as active beeds for 
optimal reccurence prevention; and 5) finally the curent in vitro and in vivo studies 
and clinical trials of nanoparticles. The current review highlighted use of nanoparticles 
as novel tools in improving drug delivery to be effective for treatment patients with 
peritoneal carcinomatosis.
                                                                             Review
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INTRODUCTION
The treatment of peritoneal surface malignancies 
has evolved extraordinarily over the years from 
cyto-reductive surgery (CRS) techniques through 
intraperitoneal drug delivery to intraoperative 
chemotherapy with hyperthermia (HIPEC) and/or post-
operative normothermic chemotherapy (EPIC) [1]. One 
of the most recent evolving intraperitoneal delivery 
systems is PIPAC (Pressurized IntraPeritoneal Aerosol 
Chemotheprapy) [2, 3], which is performed with palliative 
intent or before HIPEC in selected cases [4]. It is also 
used as intraperitoneal neoadjuvant therapy that can be 
combined with systemic neoadjuvant chemotherapy to 
induce responsiveness with CRS+HIPEC to treat with 
curative intent patients. The cytostatics do not remain 
in the abdominal cavity for prolonged periods of times 
particularly small molecular weight chemotherapeutics, 
which are quickly absorbed into the circulation [5, 6]. 
The ideal drug for intraperitoneal administration should 
remain active in the peritoneal cavity for prolonged 
period of time to avoid systemic absorption and toxicity. 
In addition, it should be a selective target for the 
tumor cells with deep penetration into tumor nodules 
[7, 8]. Currently, most of the HIPEC, EPIC and PIPAC 
procedures are using the intravenous formulation of 
chemotherapeutic agents.
The rationale for using nanoparticles (NPs) in the 
treatment of peritoneal carcinomatosis is to take advantage 
of the anti-cancer therapy as potential target for longer 
effectiveness in the peritoneal cavity. The high intracellular 
concentrations of nanoparticles can be achieved because 
they are able to enter the cells without being recognized 
by P-glycoprotein, which is one of the most important 
mechanisms in drug resistance [9]. Nanoparticles work as 
carriers of chemotherapeutics selectively target the tumor 
cells [10]. Twelve nanomedicines are clinically approved 
as anti-cancer drugs but their intraperitoneally use has 
not been reported [11]. However, the peritoneum can be 
targeted with NPs [12, 13] and EPIC can be performed 
using NPs carrying chemotherapeutics as metronomic 
therapy. The NPs can also be used for HIPEC or PIPAC. 
The depot systems such as hydrogels have some problems 
of homogeneus distribution and tolerance was investigated 
to achieve the sustained release of NPs.
The large surface area of the peritoneum, presence 
of adhesions, mucus, fluid and effects of gravity make 
intraperitoneal delivery of chemotherapy challenging. 
Many of the intravenous formulations are currently use 
the off-label for HIPEC and PIPAC which are susceptible 
to rapid clearance, exhibit local toxicity have limited 
penetration depths [14]. Nanoparticles with their sub-
micron size, versatility of physical, chemical properties 
and easily modifiable surface are uniquely poised to bypass 
the body clearing systems. They penetrate through extra- 
and intracellular barriers to deliver drugs into cancer cells 
thereby enhancing chemotherapeutic efficacy. Specific 
manipulation of the chemical composition of nanoparticles 
can significantly increase peritoneal residence time, 
thereby prolonging exposure of tumor to chemotherapeutic 
agents will increase the local drug concentration is primary 
goal of intraperitoneal chemotherapy [15].
The latest advances in the field of nanoparticles and 
their application to precision diagnostics and improved 
treatment strategies for peritoneal carcinomatosis (PC) 
will be discussed. These advances will likely develop both 
the HIPEC and PIPAC methods that were tested in in vitro 
and in vivo studies. We will discuss: 1) Nanoparticles as 
drug delivery systems; 2) Nanoparticles and Near Infrred 
(NIR) Irradiation; 3) use of nanoparticles in perioperative 
diagnostic and individualized treatment planning; 4) use 
of nanoparticles as anticancer dressing’s, hydrogels and 
as active beeds for optimal reccurence prevention; and 5) 
finally the current in vitro and in vivo studies and clinical 
trials of nanoparticles. 
Nanoparticles as drug delivery systems
Nanocarriers are the epitome of rational drug design 
with advancements in material science allowing for the 
manufacture of nanoparticles optimized for desired mode 
of delivery, location within the body, and characteristics of 
the tumor. These advantages offer an exciting prospect for 
improving the therapeutic index of chemotherapy drugs, 
overcoming drug resistance mechanisms and enhancing 
tumor penetration [16–18]. The important for the treatment 
of peritoneal surface malignancies that that has limited 
response to systemic chemotherapy since no current 
approved Food and Drug Administration (FDA) drugs for 
intraperitoneal treatment [19]. The following section will 
provide an overview of nanoparticle technologies used for 
intraperitoneal cancer drug delivery.
Advantages of using nanoparticles as drug 
delivery vehicles in the peritoneum 
Nanoparticles delivered intravenously or 
intraperitoneally selectively localize to tumor through 
passive and active targeting mechanisms. Passive 
accumulation of nanoparticles is mediated by enhanced 
permeability and retention effect (EPR), which relies 
on imperfections in tumor architecture for intratumoral 
accumulation, and retention due to diminished 
lymphatic recovery by the tumor [20]. Active targeting 
is achieved through the addition of specific moieties 
to the surface of nanoparticles that can interact with a 
wide range of molecular targets to enhance nanoparticle 
localization to tumors. The availability of biodegradable 
slow-release formulations and offers the prospect of 
long-acting intraperitoneal chemotherapy. Xu and 
colleagues developed a biodegradable Paclitaxel-loaded 
thermosensitive hydrogel system that demonstrated 
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enhanced cytotoxicity to CT26 cells, residence time 
upward of 96 hrs compared to 24 hrs for Taxol® and 
excellent biocompatibility [21]. 
In addition to rapid clearance, many existing 
chemotherapeutic agents effective for IV treatment of 
peritoneal malignancies are either highly hydrophobic 
or toxic to peritoneal tissues [22–25]. Sequestering 
drugs within nanoparticles allows delivery of highly 
hydrophobic drugs into the peritoneum and minimizing 
toxicity to healthy tissues by eliminating solvents or 
carriers. The use of nanocarriers also increases the 
intraperitoneal and intratumoral concentration of drugs 
as well as the maximize the tolerated dose compared 
to conventional formulations [26]. For example, 
nanoparticle formulation of paclitaxel (Nanotax®) at 
doses up to 275 mg/m2 was delivered intraperitoneally 
with no Grade 2, 3, or 4 neutropenia compared to Grade 
4 neutropenia at 175 mg/m2 of standard formula of 
paclitaxel [27]. Differences in sampling methods and 
data reporting preclude the comparisons of efficacy and 
pharmacokinetics of standard versus nanoparticle drug 
formulations. Available pharmacokinetics data from 
selected studies are summarized in Table 1. 
While most of the literature on the intraperitoneal 
use of nanoparticles has focused on nanoparticle delivery 
of chemotherapeutic or imaging agents, some studies 
have explored the possibility of using nanoparticles as 
palliative therapy to prevent peritoneal adhesions and 
scarring [29]. Such of these studies showed that tanshinone 
IIA loaded nanoparticles delivered intravenous (IV) was 
successfully prevented peritoneal adhesions in rats by 
upregulating fibrinolysis [30]. Alternatively, developing of 
tissue plasminogen activator loaded with thermosensitive 
hydrogel exhibited an excellent anti-adhesion effect 
in a rat model that repeated-injury of intraperitoneal 
adhesions [31]. 
Types of nanocarriers
A variety of materials including polymers 
(dendrimers, nanospheres, nanoparticles, polymer-drug-
conjugates, injectable and implantable depots), lipids 
(liposomes, solid lipid nanoparticles), metals (quantum 
dots, gold nanoshells), and carbon (buckyballs, nanotubes) 
are available for nanoparticle synthesis. Selection of 
material depends on the desired properties of the final 
nanoparticle as well as characteristics of the intended 
drug cargo such as hydrophobicity and susceptibility 
to enzymatic degradation. Polymers and lipids have 
received special attention for use in drug delivery system 
because of their excellent biocompatibility and versatility 
as well as their promising results from in vivo studies of 
intraperitoneal delivery [32, 33]. The list of nanocarriers 
that have been used so far in medicine is summerized in 
Table 2.
Overview of nanoparticle types
The shape and architecture of nanoparticles 
determine how the drug is affixed to the carrier and 
transported in the body. Drugs can be absorbed onto, 
encapsulated within, conjugated to or absorbed into 
nanocarriers. Drugs can also be loaded into nanoparticles 
using self-assembling hydrophobic/hydrophilic micelles, 
direct conjugation via chemical synthesis, self-assembled. 
Drug loaded nanoparticles have several mechanisms 
to release of the encapsulated material, including light 
triggers (near-infrared, ultra-violet), thermal stimulation, 
magnetic guidance, ultrasound, electrical stimulation and 
endogenous gradients which can be dependent on pH, 
enzymatic concentrations or redox potential [51, 52]. 
Table 3 provides the brief descriptions of nanoparticles 
with peritoneal applications.
Challenges in intraperitoneal nanoparticle drug 
delivery
Nanoparticles face multiple physical and biological 
barriers on the way to their target. Increasing the number 
of barriers resulted in diminishing scale of the targets. 
These barriers include reticular structures, lumens of small 
capillaries, endothelial covering of vessels, epithelium 
and stroma of tumors, cell membranes, and nuclear 
membranes. Additional challenges in the peritoneum 
include achieving its distribution in the cavity due to the 
presence of organs, mucus, fluid, effects of gravity, and 
micro-scale obstacles such as phagocytosis that remove 
by macrophages and clearance through lymphatics. The 
distribution of nanoparticles can be physically improved 
through manipulation of organs and positional changes, 
adverse effects of mucus and premature clearance. A 
review of human and animal peritoneal physiology studies 
reveals several important considerations for the design of 
intraperitoneal therapeutics including: 1. higher molecular 
weight and diameter of prolong peritoneal residence time, 
2. lymphatic drainage is the major route of removal of 
intraperitoneally delivered drugs, 3. peritoneal capillary 
membrane transports water and water-soluble substances 
through 4 nm pores and proteins through 25 nm pores 
and 4. negatively charged agents are rapidly cleared from 
the peritoneum, while positively charged agents exhibit 
increased retention time [67, 68]. Previously considerable 
effort has been devoted to develop a nanocarrier that 
optimized for peritoneal delivery, including manipulation 
of size, surface charge and PEG coating.
Studies of nanoparticle-mucus interactions reveal that 
mucus interferes with penetration of nanoparticle through 
hydrogen bonding, adhesion, and electrostatic interactions 
[69]. PEG coating has been used to minimize mucus-
nanoparticle interaction thereby increasing nanoparticle 
penetration through mucus [70]. To achieve the target, 
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alternative strategies include conjugation of mucolytic to the 
nanoparticle surface or the extensive mucin content of mucus 
has been used. It is important to consider the toxicity effects 
of intraperitoneal delivery of nanoparticles. These effects 
include systemic penetration, splenic and liver accumulation, 
and inflammatory responses in the peritoneum. The safety 
findings from selected studies of intra-peritoneal (IP) 
nanoparticle delivery are summarized in Table 4.
Table 1: Comparisons of efficacy and pharmacokinetics of standard versus nanoparticle drug 
formulations
Drug Exposure Time Cmax IPmg/L
Cmax Plasma
mg/L
Paclitaxel [28] 2 hours 46.61 0.112
Nab-PTX [36] Not reported 40.622 0.138
Nanotax® [120] 30–60 minutes 5.723 0.004
1Dose of 175 mg/m2 measured at 2 hours in 12 patients. 
2Doses of 35–112.5 mg/m2 measured at 0, 1, 2, 4, 6, 8, 24 and 48 hours over 1 cycle (Days 1 and 15) in 8 patients.
3Doses of 50–275 mg/m2 measured at 2 hours in 13 patients.
Table 2: Types of nanocarriers used in clinical applications
Type of nanocarriers Examples Advantages Application









- advanced prostate cancer 
- non-small cell lung cancer and 
breast cancer [35]
- intraperitoneal treatment [36]
- peritoneal metastasis in gastric 
cancer [37]





- modifies the surface of a variety of 
nanoparticles
- improves in-vivo stability
- preventing opsonization and 
phagocytosis 
- diminishing clearance by the 
reticuloendothelial system [39, 40]
- imaging and therapy [39]
- drug delivery in the 
peritoneum [41]
Liposomes [43] - approved by the FDA [42]
- susceptibility to opsonization and 
clearance by the reticulo-endothelial 
system
- increase likelihood of lodging in the 
lymph nodes
- propensity to liposomal vesicle 
destabilization [44, 45]
- ready availability 
- non-toxic, 
- biodegradable 
- unique structure that creates two 
separate compartments for entrapment 
for both lipophilic and hydrophobic 
compounds [46, 47]
- ovarian cancer [48]
- drug encapsulation and 
loading
- controlled rate of drug release 
[49, 50]
PEG - polyethylene glycol; PLGA - poly(lactic-co-glycolic acid).
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Surface modifications for targeting of peritoneal 
malignancies
The search for molecular targets to enhance 
target the tumor by the nanoparticle has yielded several 
candidates with potential for clinical utilization. These 
candidates include folic acid and transferrin which 
are showing the most effective enhancers [72–76]. An 
alternative targeting strategy involves is encapsulation 
of targeted therapeutic agent in non-targeted nanocarrier 
[77]. Currently, the bevacizumab and pemetrexed only 
target therapeutics have been used in the peritoneal 
cavity. Bevacizumab was successfully used as a 
palliative treatment of malignant ascites in peritoneal 
carcinomatosis of ovarian origin [78]. Pemetrexed (folic 
acid targeting drug) used in Phase I trial for treatment of 
optimally debulked ovarian, peritoneal, and tubal cancers 
showed lower toxicity and efficacy compare to other 
chemotherapeutic agents [79, 80].
Nanoparticles and near infrared (nir) 
irradiation
Many advances listed for the aforementioned 
drug delivery systems (DDS) that encourage number of 
groups to explore the great effect of dual combination of 
external excitatory source and nanoparticle based DDS 
[81, 82]. The investigations have entailed to use different 
types of external energy sources to activate or control 
the drug release [83]. This approach via the anticancer 
hyperthermia techniques method has been quickly adopted 
and focused on the Near Infrared (NIR) Irradiation to take 
the therapeutic advantages of specific effects to deliver the 
nanoparticles [84, 85]. 
NIR irradiation identified 200 years ago and its 
used in nanomedical since 1990s [86]. NIR irradiation 
represents specific electromagnetic wave that exhibiting 
both wave and particle properties to be strongly absorbed 
by water, hemoglobin and myoglobin. As demonstrated 
Table 3: Types and peritoneal cancer applications of nanoparticles
Type Description Applications
Liposomes
Colloidal particles composed of phospholipids. 
On contact with water, hydrophobic and 
hydrophilic components
Mirvetuxumab soravansine in combination with 
pegylated liposomal doxorubicin in adults with 
folate receptor alpha positive primary peritoneal 
cancer [53]
Intraperitoneal delivery of paclitaxel [54]
Nanospheres Solid spherical structures composed of a matrix into which a drug is disbursed
IP injection for in vivo imaging of intraperitoneal 
tumors [55]
Micelles
Self-assembling spherical structures with an 
inner hydrophobic core and an outer hydrophilic 
shell
IP delivery of paclitaxel-loaded micelles to treat 
ovarian cancer [56]
Prevention of peritoneal adhesions [28]
Injectable and 
implantable depots
Macroscale deposits of liquid or gel-like matrix 
containing a therapeutic agent or nanoparticles 
loaded with a therapeutic agent
Intraperitoneal chemotherapy with extended 
residence time and slow release
Hyaluronic acid-based hydrogels for delivery of 
paclitaxel to treat peritoneal tumors [57] 
Hyaluronic acid-based hydrogels for delivery of 
cisplatin for treatment of disseminated gastric 
cancer [58] 
Prevention of peritoneal adhesions [59, 60] 
Expansile 
Nanoparticles
Environment-responsive spheres that expand and 
release contents in response to a programmed 
stimulus such as pH
pH-triggered intraperitoneal delivery of 
chemotherapy [61]
Paclitaxel loading for intraperitoneal delivery 
with extended release time [61, 62]
Gelatin nanoparticles
Solid spheres composed of natural, non-toxic 
biopolymer in micro- or nano-size range
Gelatin nanoparticles for paclitaxel delivery 
in mouse model of disseminated peritoneal 
cancer [63] 
Suppression of peritoneal fibrosis using siRNA-
conjugated gelatin microspheres [64] 
Bioadhesive 
nanoparticles
Polylactic acid-based copolymer nanoparticles Adhesion to proteins allows longer residence 
time in the peritoneum [65] 
Mesoporous silica 
nanoparticles
Biocompatible, biodegradable spheres with 
pores of adjustable sizes allowing drug loading 
and modifiable drug release rate
Mesoporous silica nanoparticles improve paclitaxel 
loading and peritoneal residence time [66] 
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in experimental animal models, this type of irradiation 
noninvasively delivers energy to cytochrome C oxidase 
by stimulating the respiratory chain enzyme (Complex 
IV) and leads to increased adenosine triphosphate (ATP) 
production [87, 88]. The most important therapeutic 
useful effect in targeted tumor involves hyperthermia 
implementation when the nanoparticles used for 
phototherapy-based therapeutic strategies [89–93]. The 
main specific effects of NIR irradiation and nanoparticle 
implantation are favored and/or considered most important 
to cancer treatment are summarized in Table 5.
There have been only a few published papers 
that have fully referred to the potential use and initial 
experimental effects of nanoparticles and NIR for 
HIPEC and none for PIPAC. One of the first publications 
addressing this topic is detailed review suggested that the 
NIR/nanoparticle concept could improve HIPEC [102]. 
They further discussed the current three main types of 
nanoparticles including: carbon nanotubes, metal and 
magnetic nanoparticles. Moreover, Single Walled Carbon 
Nanotubes (SWNT) is more efficient than gold nanoshells 
when its stimulated by infrared light and when SWNT 
stimulated by radiofrequency induces much higher 
temperature. 
Wu et al. tested nanoparticle-induced intraperitoneal 
hyperthermia and targeted photoablation on ovarian cancer 
using ID8 cells and non-scid mouse with artificially 
induced PC using ID8-luc cells (C57BL/6 origin) [103]. 
They used pegylated silica-core gold nanoshells (pSGNs) 
with external near-infrared (NIR) laser irradiation and 
found that repeated photothermal treatment can effectively 
eliminate intraperitoneal tumors. Furthermore, they 
found that conjugation of pSGNs with anti-human CD47 
monoclonal antibody enhanced targeted intraperitonal 
anti cancer therapy. Their findings raised the possibility 
of repeated non-invasive photoablative therapeutic 
interventions after initial HIPEC. The number of 
promising nanomaterials for NIR-induced hyperthermia 
increased but their cytotoxicity and systemic impact need 
more evaluation [104].
Nanoparticles in perioperative diagnostic 
Over the last few years there are improvements 
in the treatment of patients with peritoneal metastases 
(PM) as well as diagnosis of the advance stage of the 
disease by using the fluorophore nanoparticles. The new 
era of surgical guide with molecular navigation helped 
in detection of tumor in lymph nodes, vessels and vital 
structures and lead to improve the surgical precision. 
The fluorphores are visible in the near-infrared light 
range (700–900 nm) [105]. It can be visualized using a 
special camera with light emitting diodes (LED) when 
it injected into the patient [106]. The LED produce is 
a beam with near-infrared wavelength to which the 
fluorophore responds and emits another wavelength of 
near-infrared light that can be detected with a camera 
[107]. Many new nanoparticles have been developed that 
are widely used in sentinel node biopsy, visualization of 
gastrointestinal structures, ureter visualization, and tumor 
visualization as well as peritoneal spread [108–112]. Real 
time visualization of fluorphores may help in optimizing 
the planning of surgical procedures, the protection of 
important vital structures such as the ureter or common 
bile duct, visualization of blood vessels or nerves, 
obtaining a negative resection margin and detection of 
small tumor deposits. The limitation of NIRF (near-
infrared fluorescent) guided surgery is small detection 
depth (about 5–8 mm) [107]. Currently, the mostly 
widely fluorophores that approved for use in humans 
are indocyanine green (ICG), methylene blue (MB) that 
represents some NIRF properties, 5-aminolevulinic acid 
(5-ALA), and fluorescein. In cytoreductive surgery (CRS) 
and HIPEC, we can use NIRF-guided nanoparticles like 
Table 4: Conclusions from select studies/trials of intraperitoneal nanoparticle safety
Nanoparticle Study Year Results 
Animal studies
Microspheres Kohane at al. [40] 2006
Microspheres induced 
inflammation
Liver and splenic sequestration 
with foamy macrophages
Human studies
Paclimer microspheres Phase I Trial [25] 2006 Microspheres induced 
inflammation; study discontinued
Pegylated liposomal Doxorubicin (with 
HIPEC at the time of CRC) Phase I trial [71] 2008
Well tolerated
Nanotax® (nanoparticulate paclitaxel Phase I Trialm [25] 2015
Well tolerated with minimal 
systemic exposure and reduced 
toxicity compared to IV 
paclitaxel
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MB for visualization of important structures such as 
the ureter, which is extremely important in reoperations 
[110]. NIRF nanoparticles are also used in the detection 
of peritoneal spread. One study has used tumor specific 
fluorescence imagining to target over expressed folate 
receptor-α in ovarian cancer and more tumor deposits were 
visualized using NIRF nanoparticle than with the naked 
eye [111]. The visualization with targeted NIR fluorphores 
in CRS and HIPEC procedures may result in more efficient 
cytoreduction due to more precise resection of even the 
smallest tumor nodules [111]. Another study from the same 
team also analyzed the sensitivity and diagnostic accuracy 
of α(v)β(3)-integrin-targeted NIRF compound in ovarian 
cancer and found it has 95% sensitivity, 88% specificity, 
and 96.5% diagnostic accuracy [113]. Optimization of 
molecular imaging that combines immunological probes 
with fluorophores in order to improve cancer detection is 
actively being pursued [114]. Currently, there are clinical 
3 trials to evaluate NIRF technology for the detection of 
peritoneal spread (NCT02032485, NCT01982227, NCT 
01834469). The pilot study results from the first trial 
(NCT02032485) showed evaluation of NIRF imagining 
in peritoneal metastases detection due to colorectal 
cancer [115]. Intravenous indocyanine green (ICG) was 
intraoperatively applied to 63 of 78 peritoneal resected 
nodules in 14 patients. These data showed that the 
fluorescence and final pathological examination are 84% 
malignant and 16% benign. Moreover, in 4 of 14 (29%) 
patients surgery the fluorescent detection was adjusted 
because of the additional PM not detected by naked eye 
visualization and palpation. The data from the pilot study 
concluded that ICG fluorescence imaging appears to be 
particularly useful for non-mucinous PM of colorectal 
origin. The visualization of PM in gastric cancer mouse 
model using ICG combined with antibodies against 
CEA or EGFR was reported [112]. The potential of near 
Table 5: Data from in vitro and in vivo studies described the main specific effects of Near-infrared 
(NIR) irradiation use combined of nanoparticle implementation potentially prospectively that 
useful in HIPEC and PIPAC
Selected specific effects of the NIR 
irradiation use combined with 
nanoparticle implementation
Possible practical application Reference
Hyperthermia
The possible usage of NIR induced 
hyperthermia for example using the 
phenomenon of surface plasmon resonance 
effect to destroy only cancer cells.
Chatterjee DK et al. 2011 [91]
Margheri G. et al. 2016 [92]
Huff TB et al. 2007 [93]
Fully localized (targeted) therapy
The use of NIR and selected nanoparticles 
allows for fully targeted anticancer treatment 
i.e. in intratumoral nanospheres–cytostatics 
systems application or selective anatomical 
distribution with subsequent radiation. 
Such therapy could prospectively acts more 
sparing on healthy cells and tissues.
Gupta S. et al. 2012 [94]
Hong C. et al. 2011 [95]
The possibility of multiple 
therapeutic interventions
The use of a representative group of 
nanoparticles allows the multiple NIR 
intervention in case of the planed interval 
treatment or rapid progression.
Krishnan S. et al. 2010 [96]
Chitgupi U. et al. 2017 [97]
Radiation dose enhancement
Some authors suggested that selected 
nanoparticles such as gold nanoparticles 
could be used to enhance the radiation dose 
with good anticancer effects.
Hainfeld JF. et al. 2004 [98]
Chen CW. et al. 2014 [99]
Precise control over the released 
dosage
In some applications of nanoparticle based 
DDS the amount of the released anticancer 
molecules could be well-tuned by altering 
the time duration and intensity of NIR 
light exposure. This specific effect and 
property is especially important in practical 
application when the depot form of nano-
DDS is used
Bagheri A. et al. 2016 [100]
Carling CJ et al. 2015 [101]
Oncotarget78215www.impactjournals.com/oncotarget
infrared photoimmunotherapy in peritoneal carinomatosis 
was reported in ovarian origin of mouse model [116]. The 
utility of ICG with other probes was demonstrated using 
a liposomal synthesized ICG liposomal derivative [117]. 
Another potential 5-ALA fluorophore demonstrated 
in PM evaluated the best pre-operation application 
time and the dose for intraoperative detection of 
peritoneal metastases in ovarian cancer patients [118]. 
In addition, 5-ALA was used for detection of staging of 
laparoscopic gastric cancer surgery [119, 120]. These 
studies evaluated the peritoneal visualization after 
chemotherapy by conventional laparoscopy in 12 of 38 
patients with advanced gastric cancer and peritoneal 
metastases. Additional 4 patients were positive for 
peritoneal metastases with laparoscopy and 5-ALA 
visualization and interestingly 3 of these 4 patients were 
negative by peritoneal washing cytology analysis [120]. 
Combination of 5-ALA fluorescence detection with 
molecular analysis of specific genes that mediate 5-ALA 
transport, such as peptide transporter PEPT1 (ALA influx 
transporter). PEPT1 was overexpressed in tumors suggest 
that evaluation of the expression of PEPT1 may help in 
the selection of patients who will benefit from 5-ALA 
visualization of tumor deposits [121]. 
Nanoparticles as anticancer dressing’s, hydrogels 
and as active beads used for optimal recurrence 
prevention
The preclinical studies from using of novel 
DDS systems based on nanoparticles for the treatment 
and diagnosis in the peritoneal surface malignancy 
could lead to new applications for NP’s such as direct 
chemotherapeutics delivery into the compartment created 
after resection or before or after HIPEC and PIPAC 
procedure [122]. Fan et al. demonstrated antitumor 
effects of docetaxell/LL37 in tumor bearing mice and 
loaded thermosensitive hydrogel nanoparticles in PC 
of colorectal origin [123]. In addition, polymer-lipid 
biodegradable depot (PoLigel) used in mouse model of 
ovarian cancer for sustained intraperitoneal chemotherapy 
resulted in reduction of tumor burden supporting the 
notion that nanomaterials loaded with cytostatic could be 
used to enhance anti-tumor effects and prevent or mitigate 
recurrence [124].
Various advances in DDS for intraperitoneal 
therapy such as implants and injectable depots to 
extend the residence time of chemotherapeutic agents 
in the peritoneal cavity have been discussed [125]. 
Based on nanofibers, carbonaceous nanomaterials and 
polycaprolactone materials were evaluated and termed 
nano- desings or hybrid beads with anticancer properties 
[32, 122, 126]. The honokiol nanoparticles and called 
the forms thermosensitive hydrogel composites have 
been also used [127]. The terminology for DDS will be 
depend on number of diverse factors including: types of 
nanomaterial (i.e., biodegradable-active carriers of drug), 
pharmacodynamics and pharmacokinetic knowledge of 
the material; the particular programmable smart targeted 
drug delivery device [128, 129] and the intraoperative 
application(s) of particular depot.
Currently there are two primary direction to use the 
array of available nanoparticles to extend the residence 
time of cytostatic in the peritoneal cavity and improve 
their targeted influence [122, 130]. First is to be used 
it before HIPEC to support CRS and prospectively for 
protection with biopsy for histopathology and resections 
performed laproscopically before PIPAC procedure. 
Second is to be used it after completion of HIPEC or 
PIPAC during the last perfusion/spraying cycle or after 
the washing procedure [32]. The biodegradable depot 
solutions available are summarized in Table 6. The tumors 
following resection after organ sparing of non-anatomical 
resections parenchymal organs are detected on the liver 
surface [32]. The material used in these procedures should 
be sufficiently durable to withstand all subsequent HIPEC 
or PIPAC procedures. The second approach is not required 
any special development of materials after HIPEC or 
PIPAC to avoids exposure to circulating/sprayed liquid or 
heat [32]. The large challenge is to find the depot forms 
that meet specific product characteristics and important 
following requirements; full cytotoxicity without side 
effects, cytostatic distribution, planned biodegradation 
and physicochemical stability. Nonetheless, it is widely 
recognized that drug delivery by nanoparticles is highly 
promising and will likely follow the rigorous of preclinical 
and clinical studies develop in HIPEC and PIPAC [32, 
134–136].
In vitro, in vivo and clinical studies
Nanoparticles have a potential important role in 
cancer therapy. However, utilization of nanomaterials in 
HIPEC is a new concept. Most of the research with the 
application of nanoparticles in peritoneal carcinomatosis 
treatment has been without the use of hyperthermic 
conditions. The registered clinical studies using 
nanoprticles in peritoneal carcinoma are summarized 
in Table 7. Using nanoparticles in ovarian cancer and 
associated peritoneal carcinomatosis is the primary 
interest. Hijaz et al. evaluated the preclinical use of cerium 
oxide nanoparticles conjugated with folic acid (NCe-FA) 
for treatment of ovarian cancer. Folate receptor-α has been 
reported to be overexpressed in ovarian cancer. Exposure 
of ovarian cancer cells to NCe-FA led to the intracellular 
accumulation of drug and inhibited cell proliferation. 
Mice treated with NCe-FA compared with NCe exhibited 
decreased in tumor burden without toxicity. In addition, 
combined treatment of mice with cisplatin enhanced the 
anti-tumor action of NCe-FA [137]. 
The cytotoxicity of another folate receptor-targeted 
formulation with paclitaxel [folic acid-coupled PEGylated 
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nano-paclitaxel liposome (FA-NP)] was evaluated in 
paclitaxel-resistant SKOV3/TAX ovarian cancer cells 
and in murine model of peritoneal ovarian cancer. FA-NP 
overcame paclitaxel-resistance in ovarian cancer raising the 
possibility of the FR-targeted chemoagents might prolong 
the survival in patients with drug-resistant ovarian cancer 
[138]. Another group with similar findings underscore 
the potential of folate-targeted nanoparticles containing 
chemoradiotherapy for treating ovarian peritoneal 
metastasis [139]. Most ovarian tumors and peritoneal 
implants express the CD44 receptor, a mediator of drug 
resistance that is associated with unfavorable prognosis. 
Hyaluronic acid (HA) is the ligand for CD44 promotes the 
proliferation, migration and invasion of cancer cells. Based 
on this observation HA has been evaluated for CD44-
targeted chemotherapy in ovarian cancer. Injection of HA-
based Paclitaxel (PTX)-loaded nanoparticles significantly 
reduced tumor burden compared to conventional PTX, 
thereby underscoring the promise of HA-based nano-
system for delivering PTX [140]. 
Wang et al. evaluated the preclinical effect of 
selenium (Se) nanoparticles in mouse model of peritoneal 
carcinomatosis. The Se nanoparticles were administrated 
intraperitonally prior to the injection of high malignant 
H22 hepatocarcinoma cells into the abdominal cavity. 
Overall, their findings demonstrated that Se nanoparticles 
induced of reactive oxidant species (ROS), exhibited 
potent anti-tumoral effects without induction of host 
cytotoxicity indicate the possibility of high risk to patients 
with PC [141]. 
Table 6: Potentially suitable materials possible to use in the future construction of depot supporting 
tools for HIPEC and PIPAC
Type of used material Type of experimental intervention Reference
Pegylated silica-core gold nanoshells (pSGNs) 
in vivo with external near-infrared (NIR) laser 
irradiation.
Experimental nanoparticle-induced 
intraperitoneal hyperthermia and targeted 
photoablation in treating ovarian cancer.
Wu et. al. [103]
Thermosensitive hydrogel system (PTX/
PECT(gel)) assembled by PTX (paclitaxel)-
loaded amphiphilic copolymer 
Thermosensitive hydrogel system used in 
experimental for sustained intraperitoneal 
chemotherapy of peritoneal carcinomatosis.
Xu et. al. [21]
Nanovehicles based on anti-CD133 antibodies 
bioconiugated to carbon nanotubes loaded with 
platinum (Pt) –prodrugs
Nanovehicles used as a novel target strategy for 
hyperthermic intraperitoneal chemotherapy on 
mouse melanoma B16 PC model.
Nowacki et. al. [32]
Curcumin loaded polymeric micelles (Cur-M) Anti-Tumor Activity of Curcumin by Polymeric 
Micelles in Thermosensitive Hydrogel System 
tested in Colorectal Peritoneal Carcinomatosis 
Model
Zhang et al. [131]
Paclitaxel-loaded pH-responsive expansile 
nanoparticles (Pax-eNP)
Expansile nanoparticles used in in vitro and  
in vivo murine models of malignant peritoneal 
mesothelioma
Colson et al. [142]
Paclitaxel loading nanoparticle (PLA) by 
ultrasonic emulsification
Nanoparticles tested in vitro on rat ovarian 
carcinoma cells and in vivo on PC induced in 
F344 rats
Lu et al. [132]
Combination of 5-fluorouracil (5-FU) loaded 
polymeric micelles and cisplatin (DDP) in 
biodegradable thermosensitive chitosan (CS) 
hydrogel
Nanosystems tested on colorectal peritoneal 
carcinomatosis mouse model
Yun et al. [133]
Table 7: Registered clinical studies using nanoprticles in peritoneal carcinoma
Conditions Intervention Enrollment Phase Number
Fallopian tube carcinoma Primary 
peritoneal carcinoma Recurrent ovarian 
carcinoma
Nab-PTX 51 II NCT00499252
Peritoneal carcinoma Nanotax 22 I NCT00666991
Ovarian cancer Peritoneal cavity cancer Nab-PTX 27 I NCT00825201
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A number of studies have investigated the 
application of paclitaxel (PTX) nanoparticles for peritoneal 
cancer treatment. Polymeric pH-sensitive nanoparticles 
engineered to slowly release PTX (Pax-eNP) at endosomal 
pH (pH ≤ 5), thereby allowing for extended drug action 
to deliver the chemotherapeutic drug in mouse models of 
malignant peritoneal mesothelioma. The DDS exhibited 
prolonged intraperitoneal residence time, enhanced 
cellular uptake and increased tumor affinity. It was 
approved to be effective against a mesothelioma cell line 
(MSTO-211H) in vitro, and simultaneous treatment with 
DDS of the tumor potently decreased tumor burden, initial 
intraperitoneal tumor implants and extended survival 
[142]. Pax-eNP was also evaluated in rat xenograft model 
of pancreatic peritoneal carcinomatosis using Panc-1-
cancer stem cells. They found that cancer stem cells are 
responsible for disease recurrence, therapy resistance 
and metastatic phenotype. Although nanoparticles 
loaded with PTX inhibited tumor growth to the same 
extent as PTX alone but it showed fewer side effects 
[143]. The ability of liposome-encapsulated paclitaxel 
(Nano-Taxol) to influence the stemness phenotype and 
metabolic reprogramming of a paclitaxel-resistant cell 
line was investigated. Intraperitoneal delivery of Nano-
Taxol in mouse xenograft model controls of tumor growth 
compared to standard treatment with Taxol® (intravenous 
delivery) [144].
Promising preclinical studies have led to 
introduction of nanoparticles in clinical practice. A number 
of reported advantages of using albumin nanoparticles 
loaded with PTX (nab-PTX) include: ability to delivery 
of higher dose of paclitaxel; obtain higher intratumor 
concentration of paclitaxel; easy administration and 
avoidance of Cremophor EL medium and related toxicity 
[145]. Nab-paclitaxel was used to treat 47 patients with 
platinum- and taxane-resistant ovarian cancer. Data 
showed the persistent or progressive disease following 
primary chemotherapy or recurrence within six months of 
completing treatment. Nab-PTX demonstrated significant 
clinical efficacy and was well tolerated [145]. Nab-PTX 
was also evaluated in patients with recurrent epithelial 
cancer of the ovary, fallopian tube, or peritoneum. Among 
the 44 patients who underwent treatment, 15 demonstrated 
complete and 13 partial response [146]. Nanotax®, a sterile 
nanoparticulate paclitaxel powder was used in 21 patients 
with peritoneal malignances and its intraperitoneal 
administration was well tolerated by patients with slide 
side effect. Use of DDS showed significant and prolonged 
concentrations of paclitaxel in peritoneal fluid [147]. 
Although there are small numbers of registered clinical 
trials evaluating nab-PTX for peritoneal carcinoma 
treatment, this area of clinical investigation is nonetheless 
highly promising (Table 7). Currently, clinical studies are 
evaluating the use of intraperitoneal administration of 
nanoparticles alone, without induction of hyperthermic 
conditions. Combining nanotherapy with hyperthermia 
could potentially enhance peritoneal carcinoma treatment 
and important step in the evolution of the treatment of 
peritoneal carcinomatosis. 
SUMMARY AND CONCLUSIONS
The number of HIPEC and PIPAC administrations 
performed yearly is growing systematically worldwide. 
Simultaneously, the number of fully qualified and 
reference centres offering these therapies is fortunately 
increasing as well [148, 149]. There are also many new 
studies related to development of these techniques being 
conducted such as those aimed to improve the surgical and 
technical aspects of the procedures to optimize the patient 
selection [150–152]. The large investment of resources 
correlates naturally with the emmerging social need and 
register the number of patients suffering from peritoneal 
carcinomatosis [153]. Currently, the HIPEC is fully 
recommended and recognized for treatment to increase 
patient survival with improvement this kind of therapy 
using nanomedicine [154, 155].
In the current review, we summarized the current 
use, developing concepts and strategies of nanoparticles 
in vitro, in vivo and in clinical studies and their potential 
impact on HIPEC and PIPAC. The use of nanoparticles 
as novel drug delivery systems and the evaluation 
of diverse materials in various applications has been 
area of concerted investigation pushing the frontier of 
cancer diagnostics and therapeutics. Developments of 
nanoparticle-based DDS have occurred with carbonaceous 
origin nanoparticles and gold nanoshels. Many novel 
advances have been made using of nanoparticles 
together with NIR irradiation for enhance drug delivery 
and improvements of perioperative diagnostics. The 
implementation of special beads and hydrogels in the 
construction of nanovechicles loaded with specific drug 
combinations and conjugated with select antibodies for 
targeted anti-cancer treatment has generated significant 
excitement.
In conclusion, there is large a number of 
innovative and translational studies to advance using 
of nanotechnologies as permanent treatment for 
peritoneal carcinomatosis. Several preclinical and early 
clinical studies using nanoparticle in intraperitoneal 
chemotherapeutic methods in HIPEC and PIPAC provided 
a new evidence of its effectiveness for treatment patients 
with PC. Most of the research projects have been carried 
out in vitro and in vivo models has been invaluable prior 
to clinical translation. The key issues of non-tumor 
cytotoxicity and product safety need to be fully addressed 
prior to nanoparticle implementation. We hope the new 
direction of therapy using advance nanotechnologies as 
nanoparticle-based chemotherapy will be more effective 
for treatment patients with peritoneal carcinomatosis.
Oncotarget78218www.impactjournals.com/oncotarget
Author contributions
M. Nowacki: conception and design, preparation 
of manuscript, data collection, data analysis and 
interpretation, drafting the article, approval of the final 
version. M. Peterson and T. Kloskowski: preparation of 
manuscript, data analysis and interpretation, drafting the 
article. S.L. Habib and E.A Medina edited the manuscript.
E. McCabe, D. Cortes Guiral, K. Polom, G. 
Dakwar, K. Pietkun, B. Zegarska, M. Pokrywczynska, T. 
Drewa, F. Roviello and W. Zegarski: Data analysis and 
interpretation, drafting the article.
CONFLICTS OF INTEREST
Authors declare no conflicts of interest.
REFERENCES
 1. Sugarbaker PH. Improving oncologic outcomes for 
colorectal cancer at high risk for local-regional recurrence 
with novel surgical techniques. Expert Rev Gastroenterol 
Hepatol. 2016; 10:205–213.
 2. Solass W, Kerb R, Murdter T, Giger-Pabst U, Strumberg D, 
Tempfer C, Zieren J, Schwab M, Reymond MA. 
Intraperitoneal chemotherapy of peritoneal carcinomatosis 
using pressurized aerosol as an alternative to liquid solution: 
first evidence for efficacy, Ann Surg Oncol. 2014; 21:553–559.
 3. Eveno C, Pocard M. Randomized controlled trials 
evaluating cytoreductive surgery (CRS) and hyperthermic 
intraperitoneal chemotherapy (HIPEC) in prevention and 
therapy of peritoneal metastasis: a systematic review. Pleura 
and Peritoneum. 2016; 1:169–182.
 4. Tempfer CB, Rezniczek GA, Ende P, Solass W, 
Reymond MA. Pressurized intraperitoneal aerosol 
chemotherapy with cisplatin and doxorubicin in women 
with peritoneal carcinomatosis: a cohort study. Anticancer 
Res. 2015; 35:6723–6729.
 5. Flessner MF. The transport barrier in intraperitoneal therapy. 
Am J Physiol Renal Physiol. 2005; 288:F433–F442.
 6. Dedrick RL, Flessner MF. Pharmacokinetic problems 
in peritoneal drug administration: tissue penetration and 
surface exposure. J Natl Cancer Inst. 1997; 89:480–487.
 7. Dakwar Braeckmans GR, Demeester K, Ceelen J, Smedt 
W, SCD, Remaut K. Disregarded Effect of Biological 
Fluids in siRNA Delivery: Human Ascites Fluid Severely 
Restricts Cellular Uptake of Nanoparticles. ACS Appl 
Mater Interfaces. 2015; 7:24322–24329.
 8. Flessner MF. Pharmacokinetic problems in peritoneal 
drug administration: an update after 20 years. Pleura and 
Peritoneum. 2016; 1:183–191.
 9. Cho KJ, Wang X, Nie SM, Chen Z, Shin DM. Therapeutic 
nanoparticles for drug delivery in cancer. Clin Cancer Res. 
2008; 14:1310–1316.
10. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery 
of cancer drugs. Annu Rev Med. 2012; 63:185–198.
11. Bregoli L, Movia D, Gavigan-Imedio JD, Lysaght J, 
Reynolds J, Prina-Mello A. Nanomedicine applied to 
translational oncology: a future perspective on cancer 
treatment. Nanomedicine. 2016; 12:81–103.
12. Dakwar GR, Shariati M, Willaert W, Ceelen W, De 
Smedt SC, Remaut K. Nanomedicine-based intraperitoneal 
therapy for the treatment of peritoneal carcinomatosis - 
Mission possible? Adv Drug Deliv Rev. 2017; 108:13–24. 
13. van Oudheusden TR, Grull H, Dankers PYW, de Hingh 
IHJT. Targeting the peritoneum with novel drug delivery 
systems in peritoneal carcinomatosis: a review of the 
literature, Anticancer Res. 2015; 35:627–634.
14. Los G, Verdegaal EM, Mutsaers PH, McVie JG. Penetration 
of carboplatin and cisplatin into rat peritoneal tumor nodules 
after intraperitoneal chemotherapy. Cancer Chemother 
Pharmacol. 1991; 28:159–165.
15. González-Moreno S, González-Bayón LA, Ortega-Pérez G. 
Hyperthermic intraperitoneal chemotherapy: Rationale and 
technique. World J Gastrointest Oncol. 2010; 2:68–75.
16. Soni P, Kaur J, Tikoo K. Dual drug-loaded paclitaxel–
thymoquinone nanoparticles for effective breast cancer 
therapy. J Nanopart Res. 2015; 17:18.
17. Wong C, Stylianopoulos T, Cui J, Martin J, Chauhan VP, 
Jiang W, Popović, Z, Jain RK, Bawendi MG, Fukumura D. 
Multistage nanoparticle delivery system for deep 
penetration into tumor tissue. Proc Natl Acad Sci USA. 
2011; 108:2426–2431.
18. Zhang Y, Leonard M, Shu Y, Yang Y, Shu D, Guo P, Zhang X. 
Overcoming Tamoxifen Resistance of Human Breast Cancer 
by Targeted Gene Silencing Using Multifunctional pRNA 
Nanoparticles. ACS Nano. 2016; 11:335–346.
19. Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal 
carcinomatosis from colorectal cancer. Br J Surg. 2002; 
89:1545–1550.
20. Matsumura Y, Maeda H. A new concept for macromolecular 
therapeutics in cancer chemotherapy: mechanism of 
tumoritropic accumulation of proteins and the antitumor 
agent smancs. Cancer Res. 1986; 46:6387–6392.
21. Xu S, Fan H, Yin L, Zhang J, Dong A, Deng L, Tang H. 
Thermosensitive hydrogel system assembled by PTX-
loaded copolymer nanoparticles for sustained intraperitoneal 
chemotherapy of peritoneal carcinomatosis. Eur J Pharm 
Biopharm. 2016; 104:251–259.
22. Baratti D, Kusamura S, Laterza B, Balestra MR, Deraco M. 
Early and long-term postoperative management following 
cytoreductive surgery and hyperthermic intraperitoneal 
chemotherapy. World J Gastrointest Oncol. 2010; 2:36–43.
23. Fujiwara K, Suzuki S, Ishikawa H, Oda T, Aotani E, 
Kohno I. Preliminary toxicity analysis of intraperitoneal 
carboplatin in combination with intravenous paclitaxel 
chemotherapy for patients with carcinoma of the ovary, 
peritoneum, or fallopian tube. Int J Gynecol Cancer. 2005; 
15:426–431.
Oncotarget78219www.impactjournals.com/oncotarget
24. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, 
Lewis JL, Rubin S, Curtin J, Barakat R, Phillips M. Phase I 
trial of intraperitoneal taxol: a Gynecoloic Oncology Group 
study. J Clin Oncol. 1992; 10:1485–1491.
25. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, 
Lele S, Copeland LJ, Walker JL, Burger RA, Gynecologic 
Oncology Group. Intraperitoneal cisplatin and paclitaxel in 
ovarian cancer. N Engl J Med. 2006; 354:34–43.
26. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault 
RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi 
GN, Ellerhorst JA. Phase I and pharmacokinetic study of 
ABI-007, a Cremophor-free, protein-stabilized, nanoparticle 
formulation of paclitaxel. Clin Cancer Res. 2002; 8: 
1038–1044.
27. Williamson SK, Johnson GA, Maulhardt HA, Moore KM, 
McMeekin DS, Schulz TK, Reed GA, Roby KF, 
Mackay CB, Smith HJ, Weir SJ, Wick JA, Markman M, et al. 
A phase I study of intraperitoneal nanoparticulate paclitaxel 
(Nanotax®) in patients with peritoneal malignancies. Cancer 
Chemother Pharmacol. 2015; 75:1075–1087.
28. de Bree E, Rosing H, Filis D, Romanos J, Melisssourgaki M, 
Daskalakis M, Pilatou M, Sanidas E, Taflampas P, Kalbakis 
K, Beijnen JH, Tsiftsis DD. Cytoreductive surgery and 
intraoperative hyperthermic intraperitoneal chemotherapy 
with paclitaxel: a clinical and pharmacokinetic study. Ann 
Surg Oncol. 2008; 15:1183–1192.
29. Wu Q, Li L, Wang N, Gao X, Wang B, Liu X, Qian Z, Wei 
Y, Gong C. Biodegradable and thermosensitive micelles 
inhibit ischemia-induced postoperative peritoneal adhesion. 
Int J Nanomedicine. 2014; 9:727–734.
30. Qin F, Ma Y, Li X, Wang X, Wei Y, Hou C, Lin S, Hou 
L, Wang C. Efficacy and mechanism of tanshinone 
IIA liquid nanoparticles in preventing experimental 
postoperative peritoneal adhesions in vivo and in vitro. Int J 
Nanomedicine. 2015; 10:3699–3716.
31. He T, Zou C, Song L, Wang N, Yang S, Zeng Y, Wu Q, 
Zhang W, Chen Y, Gong C. Improving Antiadhesion Effect 
of Thermosensitive Hydrogel with Sustained Release of 
Tissue-type Plasminogen Activator in a Rat Repeated-Injury 
Model. ACS Appl Mater Interfaces. 2016; 8:33514–33520.
32. Nowacki M, Wisniewski M, Werengowska-Ciecwierz K, 
Roszek K, Czarnecka J, Łakomska I, Kloskowski T, Tyloch 
D, Debski R, Pietkun K, Pokrywczynska M, Grzanka 
D, Czajkowski R, et al. Nanovehicles as a novel target 
strategy for hyperthermic intraperitoneal chemotherapy: 
a multidisciplinary study of peritoneal carcinomatosis. 
Oncotarget. 2015; 6:22776–22798. https://doi.org/10.18632/
oncotarget.4309.
33. Ye H, Karim AA, Loh XJ. Current treatment options and 
drug delivery systems as potential therapeutic agents for 
ovarian cancer: a review. Mater Sci Eng C Mater Biol Appl. 
2014; 45:609–619.
34. Thorat ND, Otari SV, Patil RM, Bohara RA, Yadav HM, 
Koli VB, Chaurasia AK, Ningthoujam RS. Synthesis, 
characterization and biocompatibility of chitosan 
functionalized superparamagnetic nanoparticles for heat 
activated curing of cancer cells. Dalton Trans. 2014; 
43:17343–51.
35. Miele E, Spinelli GP, Tomao F, Tomao S. Albumin-bound 
formulation of paclitaxel (Abraxane ABI-007) in the 
treatment of breast cancer. Int J Nanomedicine. 2009; 4: 
99–105.
36. Cristea M. Pharmacologic advantage (PA) of intraperitoneal 
(IP) nab-paclitaxel in patients with advanced malignancies 
primarily confined to the peritoneal cavity. J Clin Oncol. 
2015; 33:(suppl; abstr 2553).
37. Kinoshita J, Fushida S, Tsukada T, Oyama K, Watanabe 
T, Shoji M, Okamoto K, Nakanuma S, Sakai S, Makino I, 
Furukawa H, Hayashi H, Nakamura K, et al. Comparative 
study of the antitumor activity of Nab-paclitaxel and 
intraperitoneal solvent-based paclitaxel regarding peritoneal 
metastasis in gastric cancer. Oncol Rep. 2014; 32:89–96.
38. Ulery BD, Petersen LK, Phanse Y, Kong CS, Broderick 
SR, Kumar D, Ramer-Tait AE, Carrillo-Conde B, Rajan K, 
Wannemuehler MJ, Bellaire BH, Metzger DW, Narasimhan 
B. Rational design of pathogen-mimicking amphiphilic 
materials as nanoadjuvants. Sci Rep. 2011; 1:198.
39. Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. 
Nanoparticle PEGylation for imaging and therapy. 
Nanomedicine (Lond). 2011; 6:715–728.
40. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors 
affecting the clearance and biodistribution of polymeric 
nanoparticles. Mol Pharm. 2008; 5:505–515.
41. Kohane DS, Tse JY, Yeo Y, Padera R, Shubina M, Langer 
R. Biodegradable polymeric microspheres and nanospheres 
for drug delivery in the peritoneum. J Biomed Mater Res A. 
2006; 77:351–361.
42. Hu Y, Zeng F, Ju R, Lu W. Advances in Liposomal Drug 
Delivery System in the Field of Chemotherapy. Clin Oncol. 
2016; 1:1092.
43. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, 
Zarghami N, Hanifehpour Y, Samiei M, Kouhi M, Nejati-
Koshki K. Liposome: classification, preparation, and 
applications. Nanoscale Res Lett. 2013; 8:102.
44. Senior JH. Fate and behavior of liposomes in vivo: a review 
of controlling factors. Crit Rev Ther Drug Carrier Syst. 
1987; 3:123–193.
45. Ishida T, Harashima H, Kiwada H. Interactions of liposomes 
with cells in vitro and in vivo: opsonins and receptors. Curr 
Drug Metab. 2001; 2:397–409.
46. Dadashzadeh S, Mirahmadi N, Babaei MH, Vali AM. 
Peritoneal retention of liposomes: Effects of lipid 
composition, PEG coating and liposome charge. J Control 
Release. 2010; 148:177–186.
47. Ulrich AS. Biophysical aspects of using liposomes as 
delivery vehicles. Biosci Rep. 2002; 22:129–150.
48. Shen YA, Li WH, Chen PH, He CL, Chang YH, Chuang 
CM. Intraperitoneal delivery of a novel liposome-
encapsulated paclitaxel redirects metabolic reprogramming 
Oncotarget78220www.impactjournals.com/oncotarget
and effectively inhibits cancer stem cells in Taxol(®)-
resistant ovarian cancer. Am J Transl Res. 2015; 7:841–855.
49. Chen MX, Li BK, Yin DK, Liang J, Li SS, Peng DY. Layer-
by-layer assembly of chitosan stabilized multilayered 
liposomes for paclitaxel delivery. Carbohydr Polym. 2014; 
111:298–304.
50. Lynge ME, Laursen MB, Hosta-Rigau L, Jensen BE, Ogaki 
R, Smith AA, Zelikin AN, Städler B. Liposomes as drug 
deposits in multilayered polymer films. ACS Appl Mater 
Interfaces. 2013; 5:2967–2975.
51. Kost J, Langer R. Responsive polymeric delivery systems. 
Adv Drug Deliv Rev. 2001; 46:125–148.
52. Mura S, Nicolas J, Couvreur P. Stimuli-responsive 
nanocarriers for drug delivery. Nat Mater. 2013; 12:991–1003.
53. O’Malley DM, Martin LP, Moore KN, Nepert DL, Ruiz-
Soto R, Vergote I. FORWARD II: A phase Ib study to 
evaluate the safety, tolerability and pharmacokinetics of 
mirvetuximab soravtansine (IMGN853) in combination 
with bevacizumab, carboplatin or pegylated liposomal 
doxorubicin in adults with folate receptor alpha (FRα)-
positive advanced epithelial ovarian cancer (EOC), primary 
peritoneal, fallopian tube, or endometrial cancer. J Clin 
Oncol. 2016; 34:TPS5611–TPS5611.
54. Shen YA, Li WH, Chen PH, He CL, Chang YH, Chuang 
CM. Intraperitoneal delivery of a novel liposome-
encapsulated paclitaxel redirects metabolic reprogramming 
and effectively inhibits cancer stem cells in Taxol(®)-
resistant ovarian cancer. Am J Transl Res. 2015; 7:841–855.
55. Dong L, An D, Gong M, Lu Y, Gao HL, Xu YJ, Yu SH. 
PEGylated upconverting luminescent hollow nanospheres for 
drug delivery and in vivo imaging. Small. 2013; 9:3235–3241.
56. Cho H, Lai TC, Kwon GS. Poly(ethylene glycol)-block-
poly(ε-caprolactone) micelles for combination drug 
delivery: evaluation of paclitaxel, cyclopamine and 
gossypol in intraperitoneal xenograft models of ovarian 
cancer. J Control Release. 2013; 166:1–9.
57. Bajaj G, Kim MR, Mohammed SI, Yeo Y. Hyaluronic 
acid-based hydrogel for regional delivery of paclitaxel to 
intraperitoneal tumors. J Control Release. 2012; 158:386–392.
58. Emoto S, Yamaguchi H, Kamei T, Ishigami H, Suhara T, 
Suzuki Y, Ito T, Kitayama J, Watanabe T. Intraperitoneal 
administration of cisplatin via an in situ cross-linkable 
hyaluronic acid-based hydrogel for peritoneal dissemination 
of gastric cancer. Surg Today. 2014; 44:919–926.
59. He T, Zou C, Song L, Wang N, Yang S, Zeng Y, Wu Q, 
Zhang W, Chen Y, Gong C. Improving Antiadhesion Effect 
of Thermosensitive Hydrogel with Sustained Release of 
Tissue-type Plasminogen Activator in a Rat Repeated-Injury 
Model. ACS Appl Mater Interfaces. 2016; 8:33514–33520.
60. Xu S, Fan H, Yin L, Zhang J, Dong A, Deng L, Tang 
H. Thermosensitive hydrogel system assembled by 
PTX-loaded copolymer nanoparticles for sustained 
intraperitoneal chemotherapy of peritoneal carcinomatosis. 
Eur J Pharm Biopharm. 2016; 104:251–259.
61. Colson YL, Liu R, Southard EB, Schulz MD, Wade JE, 
Griset AP, Zubris KA, Padera RF, Grinstaff MW. The 
performance of expansile nanoparticles in a murine model of 
peritoneal carcinomatosis. Biomaterials. 2011; 32:832–840.
62. Herrera VL, Colby AH, Tan GA, Moran AM, 
O’Brien MJ, Colson YL, Ruiz-Opazo N, Grinstaff MW. 
Evaluation of expansile nanoparticle tumor localization 
and efficacy in a cancer stem cell-derived model of 
pancreatic peritoneal carcinomatosis. Nanomedicine 
(Lond). 2016; 11:1001–1015.
63. Tsai M, Lu Z, Wang J, Yeh TK, Wientjes MG, Au JL. 
Effects of carrier on disposition and antitumor activity of 
intraperitoneal Paclitaxel. Pharm Res. 2007; 24:1691–1701.
64. Obata Y, Nishino T, Kushibiki T, Tomoshige R, Xia Z, 
Miyazaki M, Abe K, Koji T, Tabata Y, Kohno S. HSP47 
siRNA conjugated with cationized gelatin microspheres 
suppresses peritoneal fibrosis in mice. Acta Biomater. 2012; 
8:2688–2696.
65. Deng Y, Yang F, Cocco E, Song E, Zhang J, Cui J, Mohideen 
M, Bellone S, Santin AD, Saltzman WM. Improved i.p. 
drug delivery with bioadhesive nanoparticles. Proc Natl 
Acad Sci USA. 2016; 113:11453–11458.
66. Fu Q, Hargrove D, Lu X. Improving paclitaxel 
pharmacokinetics by using tumor-specific mesoporous silica 
nanoparticles with intraperitoneal delivery. Nanomedicine. 
(2016; 12:1951–1959.
67. Li J, Jiang B. Studies on three-dimensional configuration 
of diaphragmatic lymphatics and absorptive mechanism of 
lymph from the peritoneal cavity. Zhongguo Yi Xue Ke Xue 
Yuan Xue Bao. 1994; 16:183–187. [Article in Chinese].
68. Flessner MF. Peritoneal transport physiology: insights from 
basic research. J Am Soc Nephrol. 1991; 2:122–135.
69. Lai SK, Wang YY, Hanes J. Mucus-penetrating 
nanoparticles for drug and gene delivery to mucosal tissues. 
Adv Drug Deliv Rev. 2009; 61:158–171.
70. Maisel K, Ensign L, Reddy M, Cone R, Hanes J. 
Effect of surface chemistry on nanoparticle interaction 
with gastrointestinal mucus and distribution in the 
gastrointestinal tract following oral and rectal administration 
in the mouse. J Control Release. 2015; 197:48–57.
71. Harrison LE, Bryan M, Pliner L, Saunders T. Phase I trial 
of pegylated liposomal doxorubicin with hyperthermic 
intraperitoneal chemotherapy in patients undergoing 
cytoreduction for advanced intra-abdominal malignancy. 
Ann Surg Oncol. 2008; 15:1407–1413.
72. Werner ME, Karve S, Sukumar R, Cummings ND, Copp JA, 
Chen RC, Zhang T, Wang AZ. Folate-targeted nanoparticle 
delivery of chemo- and radiotherapeutics for the treatment 
of ovarian cancer peritoneal metastasis. Biomaterials. 2011; 
32:8548–8554.
73. Schroeder JE, Shweky I, Shmeeda H, Banin U, Gabizon 
A. Folate-mediated tumor cell uptake of quantum dots 
entrapped in lipid nanoparticles. J Control Release. 2007; 
124:28–34.
Oncotarget78221www.impactjournals.com/oncotarget
74. Daniels TR, Bernabeu E, Rodríguez JA, Patel S, Kozman 
M, Chiappetta DA, Holler E, Ljubimova JY, Helguera G, 
Penichet ML. The transferrin receptor and the targeted 
delivery of therapeutic agents against cancer. Biochim 
Biophys Acta. 2012; 1820:291–317.
75. Krieger ML, Eckstein N, Schneider V, Koch M, Royer HD, 
Jaehde U, Bendas G. Overcoming cisplatin resistance of 
ovarian cancer cells by targeted liposomes in vitro. Int J 
Pharm. 2010; 389:10–7.
76. Wu H, Yao L, Mei J, Li F. Development of synthetic of 
peptide-functionalized liposome for enhanced targeted 
ovarian carcinoma therapy. Int J Clin Exp Pathol. 2015; 
8:207–216.
77. Blanco E, Bey EA, Khemtong C, Yang SG, Setti-Guthi 
J, Chen H, Kessinger CW, Carnevale KA, Bornmann 
WG, Boothman DA, Gao J. Beta-lapachone micellar 
nanotherapeutics for non-small cell lung cancer therapy. 
Cancer Res. 2010; 70:3896–3904
78. Jordan K, Luetkens T, Gog C, Killing B, Arnold D, Hinke 
A, Stahl M, Freier W, Rüssel J, Atanackovic D, Hegewisch-
Becker S. Intraperitoneal bevacizumab for control of 
malignant ascites due to advanced-stage gastrointestinal 
cancers: A multicentre double-blind, placebo-controlled phase 
II study - AIO SUP-0108. Eur J Cancer. 2016; 63:127–134.
79. Chambers SK, Chow HH, Janicek MF, Cragun JM, 
Hatch KD, Cui H, Laughren C, Clouser MC, Cohen JL, 
Wright HM, Abu Shahin N, Alberts DS. Phase I trial of 
intraperitoneal pemetrexed, cisplatin, and paclitaxel in 
optimally debulked ovarian cancer. Clin Cancer Res. 2012; 
18:2668–2678.
80. Lim EK, Jang E, Lee K, Haam S, Huh YM. Delivery of 
cancer therapeutics using nanotechnology. Pharmaceutics. 
2013; 5:294–317.
81. Yao J, Feng J, Chen J. External-stimuli responsive systems 
for cancer theranostic. Asian J Pharm Sci. 2016; 11:585–595.
82. Chen Q, Ke H, Dai Z, Liu Z. Nanoscale theranostics for 
physical stimulus-responsive cancer therapies. Biomaterials. 
2015; 73:214–230.
83. Huff TB, Tong L, Zhao Y, Hansen MN, Cheng JX, Wei 
A. Hyperthermic effects of gold nanorods on tumor cells. 
Nanomedicine (Lond). 2007; 2:125–132.
84. Timko BP, Arruebo M, Shankarappa SA, McAlvin JB, 
Okonkwo OS, Mizrahi B, Stefanescu CF, Gomez L, Zhu J, 
Zhu A, Santamaria J, Langer R, Kohane DS. Near-infrared-
actuated devices for remotely controlled drug delivery. Proc 
Natl Acad Sci USA. 2014; 111:1349–1354.
85. Pasquini C. Near Infrared Spectroscopy: fundamentals, 
practical aspects and analytical applications. J Braz 
Chem Soc. 2003; 14. https://doi.org/10.1590/S0103-
50532003000200006. 
86. Tanaka Y, Matsuo K, Yuzuriha S. Near-Infrared Irradiation 
Nonthermally Induces Long-lasting Vasodilation by 
Causing Apoptosis of Vascular Smooth Muscle Cells. 
Eplasty. 2011; 11:e22.
 87. Cassano P, Cusin C, Mischoulon D, Hamblin MR, De 
Taboada L, Pisoni A, Chang T, Yeung A, Ionescu DF, Petrie 
SR, Nierenberg AA, Fava M, Iosifescu DV. Near-Infrared 
Transcranial Radiation for Major Depressive Disorder: 
Proof of Concept Study. Psychiatry J. 2015; 2015:352979.
 88. Zhou L, Zhang M, Fu Q, Li J, Sun H. Targeted near infrared 
hyperthermia combined with immune stimulation for 
optimized therapeutic efficacy in thyroid cancer treatment. 
Oncotarget. 2016; 7:6878–6890. https://doi.org/10.18632/
oncotarget.6901.
 89. Kaur P, Aliru ML, Chadha AS, Asea A, Krishnan S. 
Hyperthermia using nanoparticles--Promises and pitfalls. 
Int J Hyperthermia. 2016; 32:76–88.
 90. Hung CC, Huang WC, Lin YW, Yu TW, Chen HH, Lin 
SC, Chiang WH, Chiu HC. Active Tumor Permeation 
and Uptake of Surface Charge-Switchable Theranostic 
Nanoparticles for Imaging-Guided Photothermal/Chemo 
Combinatorial Therapy. Theranostics. 2016; 6:302–317.
 91. Chatterjee DK, Diagaradjane P, Krishnan S. Nanoparticle-
mediated hyperthermia in cancer therapy. Ther Deliv. 2011; 
2:1001–1014.
 92. Margheri G, Zoppi A, Olmi R, Trigari S, Traversi R, Severi 
M, Bani D, Bianchini F, Torre E, Margheri F, Chillà A, 
Biagioni A, Calorini L, et al. Tumor-tropic endothelial colony 
forming cells (ECFCs) loaded with near-infrared sensitive Au 
nanoparticles: A „cellular stove” approach to the photoablation 
of melanoma. Oncotarget. 2016; 7:39846–39860. https://doi.
org/10.18632/oncotarget.9511.
 93. Huff TB, Tong L, Zhao Y, Hansen MN, Cheng JX, Wei 
A. Hyperthermic effects of gold nanorods on tumor cells. 
Nanomedicine (Lond). 2007; 2:125–132.
 94. Gupta S, Stafford RJ, Javadi S, Ozkan E, Ensor JE, Wright 
KC, Elliot AM, Jian Y, Serda RE, Dixon KA, Miller JJ, 
Klump S, Wallace MJ, et al. Effects of Near-infrared Laser 
Irradiation of Biodegradable Microspheres Containing 
Hollow Gold Nanospheres and Paclitaxel Administered 
Intraarterially in a Rabbit Liver Tumor Model. J Vasc Interv 
Radiol. 2012; 23:553–561.
 95. Hong C, Lee J, Zheng H, Hong SS, Lee C. Porous silicon 
nanoparticles for cancer photothermotherapy. Nanoscale 
Res Lett. 2011; 6:321.
 96. Krishnan S, Diagaradjane P, Cho SH. Nanoparticle-
mediated thermal therapy: evolving strategies for prostate 
cancer therapy. Int J Hyperthermia. 2010; 26:775–789.
 97. Chitgupi U, Qin Y, Lovell JF. Targeted Nanomaterials for 
Phototherapy. Nanotheranostics. 2017; 1:38–58.
 98. Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold 
nanoparticles to enhance radiotherapy in mice. Phys Med 
Biol. 2004; 49:N309–315.
 99. Chen CW, Chan YC, Hsiao M, Liu RS. Plasmon-
Enhanced Photodynamic Cancer Therapy by Upconversion 
Nanoparticles Conjugated with Au Nanorods. ACS Appl 
Mater Interfaces. 2016; 8:32108–32119.
100. Bagheri A, Arandiyan H, Boyer C, Lim M. Lanthanide-
Doped Upconversion Nanoparticles: Emerging Intelligent 
Oncotarget78222www.impactjournals.com/oncotarget
Light-Activated Drug Delivery Systems. Adv Sci (Weinh). 
2016; 3:1500437.
101. Carling CJ, Viger ML, Huu VA, Garcia AV, Almutairi A. 
In Vivo Visible Light-Triggered Drug Release From an 
Implanted Depot. Chem Sci. 2015; 6:335–341.
102. Levi-Polyachenko NH, Stewart IV JH. Clinical Relevance 
of Nanoparticle Induced Hyperthermia for Drug Delivery 
and Treatment of Abdominal Cancers. The Open 
Nanomedicine Journal. 2011; 3:24–37.
103. Wu CC, Yang YC, Hsu YT, Wu TC, Hung CF, Huang 
JT, Chang CL. Nanoparticle-induced intraperitoneal 
hyperthermia and targeted photoablation in treating ovarian 
cancer. Oncotarget. 2015; 6:26861–26875. https://doi.
org/10.18632/oncotarget.4766.
104. Cherukuri P, Glazer ES, Curley SA. Targeted hyperthermia 
using metal nanoparticles. Adv Drug Deliv Rev. 2010; 
62:339–345.
105. Frangioni JV. In vivo near-infrared fluorescence imaging. 
Curr Opin Chem Biol. 2003; 7:626–634.
106. Sevick-Muraca EM, Sharma R, Rasmussen JC,Marshall 
MV, Wendt JA, Pham HQ,  Bonefas E, Houston JP, Sampath 
L, Adams KE, Blanchard DK, Fisher RE, Chiang SB, et 
al. Imaging of lymph fl ow in breast cancer patients after 
microdose administration of a near-infrared fl uorophore: 
feasibility study. Radiology. 2008; 246:734–741. 
107. Polom K, Murawa D, Rho YS, Nowaczyk P, Hünerbein 
M, Murawa P. Current trends and emerging future of 
indocyanine green usage in surgery and oncology: a 
literature review. Cancer. 2011; 117:4812–4822. 
108. Polom W, Markuszewski M, Cytawa W, Czapiewski P, Lass 
P, Matuszewski M. Fluorescent versus radioguided lymph 
node mapping in blader cancer. Clin Geniotourin Cancer. 
2017; 15:e405–e409. 
109. Figueiredo JL, Siegel C, Nahrendorf M, Weissleder R. 
Intraoperative near-infrared fl uorescent cholangiography 
(NIRFC) in mouse models of bile duct injury. World J Surg. 
2010; 34:336–343.
110. Polom W, Markuszewski M, Rho YS, Matuszewski M. 
Use of invisible near infrared light fluorescence with 
indocyanine green and methylene blue in urology. Part 2. 
Cent European J Urol. 2014; 67:310–313.
111. van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis 
RG, Kelder W, Sarantopoulos A, de Jong JS, Arts HJG, van 
der Zee AG, Bart J, Low PS, Ntziachristos V. Intraoperative 
tumor-specific fluorescence imaging in ovarian cancer by 
folate receptor-a targeting: First in-human results. Nat Med. 
2011; 17:1315–19.
112. Ito A, Ito Y, Matsushima S, Tsuchida D, Ogasawara M, 
Hasegawa J, Misawa K, Kondo E, Kaneda N, Nakanishi H. 
New whole-body multimodality imaging of gastric cancer 
peritoneal metastasis combining fluorescence imaging with 
ICGlabeled antibody and MRI in mice. Gastric Cancer 
2014; 17:497–507.
113. Harlaar NJ, Kelder W, Sarantopoulos A, Bart J, 
Themelis G, van Dam GM, Ntziachristos V. Real-
time near infrared fluorescence (NIRF) intra-operative 
imaging in ovarian cancer using an α(v)β(3-)integrin 
targeted agent. Gynecol Oncol. 2013; 128:590–595. 
114. van Oosten M, Crane LM, Bart J, van Leeuwen FW, van 
Dam GM. Selecting potential targetable biomarkers for 
imaging purposes in colorectal cancer using target selection 
criteria (TASC): A novel target identification tool. Transl 
Oncol. 2011; 4:71–82.
115. Liberale G, Vankerckhove S, Caldon MG, Ahmed B, 
Moreau M, Nakadi IE, Larsimont D, Donckier V, Bourgeois 
P. Group R&D for the Clinical Application of Fluorescence 
Imaging of the Jules Bordetʼs Institute. Fluorescence 
Imaging After Indocyanine Green Injection for Detection 
of Peritoneal Metastases in Patients Undergoing 
Cytoreductive Surgery for Peritoneal Carcinomatosis 
From Colorectal Cancer: A Pilot Study. Ann Surg. 2016; 
264:1110–1115.
116. Sato K, Hanaoka H, Watanabe R, Nakajima T, Choyke PL, 
Kobayashi H. Near infrared photoimmunotherapy in the 
treatment of disseminated peritoneal ovarian cancer. Mol 
Cancer Ther. 2015; 14:141–150.
117. Hoshino I, Maruyama T, Fujito H, Tamura Y, Suganami 
A, Hayashi H,  Toyota T, Akutsu Y, Murakami K, Isozaki 
Y, Akanuma N, Takeshita N, Toyozumi T, et al. Detection 
of peritoneal dissemination with near-infrared fluorescence 
laparoscopic imaging using a liposomal formulation of 
a synthesized indocyanine green liposomal derivative. 
Anticancer Res. 2015; 35:1353–1359.
118. Hillemanns P, Wimberger P, Reif J, Stepp H, Klapdor R. 
Photodynamic diagnosis with 5-aminolevulinic acid for 
intraoperative detection of peritoneal metastases of ovarian 
cancer: A feasibility and dose finding study. Lasers Surg 
Med. 2016; 49:169–176.
119. Murayama Y, Ichikawa D, Koizumi N, Komatsu S, Shiozaki 
A, Kuriu Y,  Ikoma H, Kubota T, Nakanishi M, Harada Y, 
Fujiwara H, Okamoto K, Ochiai T, et al. Staging fluorescence 
laparoscopy for gastric cancer by using 5-aminolevulinic 
acid. Anticancer Res. 2012; 32:5421–5427.
120. Kishi K, Fujiwara Y, Yano M, Motoori M, Sugimura 
K, Takahashi H, Ohue M, Sakon M. Usefulness of 
diagnostic laparoscopy with 5-aminolevulinic acid (ALA)-
mediated photodynamic diagnosis for the detection 
of peritoneal micrometastasis in advanced gastric cancer 
after chemotherapy. Surg Today. 2016; 46:1427–1434.
121. Yonemura Y, Canbay E, Ishibashi H, Nishino E, Endou Y, 
Sako S, Ogura S. 5-Aminolevulinic Acid Fluorescence in 
Detection of PeritonealMetastases. Asian Pac J Cancer Prev. 
2016; 17:2271–2275.
122. Nowacki M, Jundziłł A, Bieniek M, Kowalczyk T, 
Kloskowski T, Drewa T. Modern biomaterials as hemostatic 
dressings in kidney nephron sparing surgery (NSS)-murine 
model. A preliminary report. Polim Med. 2012; 42:35–43.
Oncotarget78223www.impactjournals.com/oncotarget
123. Fan R, Tong A, Li X, Gao X, Mei L, Zhou L, Zhang X, You 
C, Guo G. Enhanced antitumor effects by docetaxel/LL37-
loaded thermosensitive hydrogel nanoparticles in peritoneal 
carcinomatosis of colorectal cancer. Int J Nanomedicine. 
2015; 10:7291–7305.
124. Zahedi P, Stewart J, De Souza R, Piquette-Miller M, Allen 
C. An injectable depot system for sustained intraperitoneal 
chemotherapy of ovarian cancer results in favorable drug 
distribution at the whole body, peritoneal and intratumoral 
levels. J Control Release. 2012; 158:379–385.
125. De Smet L, Ceelen W, Remon JP, Vervaet C. Optimization 
of Drug Delivery Systems for Intraperitoneal Therapy to 
Extend the Residence Time of the Chemotherapeutic Agent. 
Scientific World Journal. 2013: 720858.
126. Nowacki M, Wiśniewski M, Werengowska-Ciećwierz 
K, Terzyk AP, Kloskowski T, Marszałek A, Bodnar M, 
Pokrywczyńska M, Nazarewski Ł, Pietkun K, Jundziłł 
A, Drewa T. New application of carbon nanotubes in 
haemostatic dressing filled with anticancer substance. 
Biomed Pharmacother. 2015; 69:349–354.
127. Xie Y, Long Q, Wu QJ, Shi S, Dai M, Liu Y, Liu L, 
Gong C, Qian Z, Weia Y, Zhao X. Improving therapeutic 
effect in ovarian peritoneal carcinomatosis with honokiol 
nanoparticles in a thermosensitive hydrogel composite. 
RSC Adv. 2012; 2:7759–7771.
128. Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, 
Pandey P, Bannerjee SK. Drug delivery systems: An 
updated review. Int J Pharm Investig. 2012; 2:2–11.
129. Singh R, Lillard JW Jr. Nanoparticle-based targeted drug 
delivery. Exp Mol Pathol. 2009; 86:215–223.
130. Tang Q, Wang Y, Huang R, You Q, Wang G, Chen Y, Jiang 
Z, Liu Z, Yu L, Muhammad S, Wang X. Preparation of 
anti-tumor nanoparticle and its inhibition to peritoneal 
dissemination of colon cancer. PLoS One. 2014; 9:e98455.
131. Zhang W, Cui T, Liu L, Wu Q, Sun L, Li L, Wang N, 
Gong C. Improving Anti-Tumor Activity of Curcumin by 
Polymeric Micelles in Thermosensitive Hydrogel System 
in Colorectal Peritoneal Carcinomatosis Model. J Biomed 
Nanotechnol. 2015; 11:1173–1182.
132. Lu H, Li B, Kang Y, Jiang W, Huang Q, Chen Q, Li L, 
Xu C. Paclitaxel nanoparticle inhibits growth of ovarian 
cancer xenografts and enhances lymphatic targeting. Cancer 
Chemother Pharmacol. 2007; 59:175–181.
133. Yun Q, Wang SS, Xu S, Yang JP, Fan J, Yang LL, Chen 
Y, Fu SZ, Wu JB. Use of 5-Fluorouracil Loaded Micelles 
and Cisplatin in Thermosensitive Chitosan Hydrogel 
as an Efficient Therapy against Colorectal Peritoneal 
Carcinomatosis. Macromol Biosci. 2016. [Epub ahead 
of print].
134. Lu Z, Wang J, Wientjes MG, Au JL. Intraperitoneal therapy 
for peritoneal cancer. Future Oncol. 2010; 6:1625–1641.
135. Zhang H, Tian Y, Zhu Z, Xu H, Li X, Zheng D, Sun W. 
Efficient antitumor effect of co-drug-loaded nanoparticles 
with gelatin hydrogel by local implantation. Sci Rep. 2016; 
6:26546.
136. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, 
Langer R. Nanocarriers as an emerging platform for cancer 
therapy. Nat Nanotechnol. 2007; 2:751–760. 
137. Hijaz M, Das S, Mert I, Gupta A, Al-Wahab Z, Tebbe 
C, Dar S, Chhina J, Giri S, Munkarah A, Seal S, Rattan R. 
Folic acid tagged nanoceria as a novel therapeutic agent in 
ovarian cancer. BMC Cancer. 2016; 16:220.
138. Tong L, Chen W, Wu J, Li H. Folic acid-coupled nano-
paclitaxel liposome reverses drug resistance in SKOV3/TAX 
ovarian cancer cells. Anticancer Drugs. 2014; 25:244–254.
139. Werner ME, Karve S, Sukumar R, Cummings ND, Copp 
JA, Chen RC, Zhang T, Wang AZ. Folate-targeted 
nanoparticle delivery of chemo- and radiotherapeutics 
for the treatment of ovarian cancer peritoneal metastasis. 
Biomaterials. 2011; 32:8548–8554.
140. Wang L, Jia E. Ovarian cancer targeted hyaluronic acid-
based nanoparticle system for paclitaxel delivery to 
overcome drug resistance. Drug Deliv. 2016; 23:1810–1817.
141. Wang X, Sun K, Tan Y, Wu S, Zhang J. Efficacy and safety 
of selenium nanoparticles administered intraperitoneally for 
the prevention of growth of cancer cells in the peritoneal 
cavity. Free Radic Biol Med. 2014; 72:1–10
142. Colson YL, Liu R, Southard EB, Schulz MD, Wade 
JE, Griset AP, Zubris KA, Padera RF, Grinstaff MW. The 
performance of expansile nanoparticles in a murine model of 
peritoneal carcinomatosis. Biomaterials. 2011; 32:832–840.
143. Herrera VL, Colby AH, Tan GA, Moran AM, O’Brien 
MJ, Colson YL, Ruiz-Opazo N, Grinstaff MW. 
Evaluation of expansile nanoparticle tumor localization 
and efficacy in a cancer stem cell-derived model of 
pancreatic peritoneal carcinomatosis. Nanomedicine 
(Lond). 2016; 11:1001–1015.
144. Shen YA, Li WH, Chen PH, He CL, Chang YH, Chuang 
CM. Intraperitoneal delivery of a novel liposome-
encapsulated paclitaxel redirects metabolic reprogramming 
and effectively inhibits cancer stem cells in Taxol(®)-
resistant ovarian cancer. Am J Transl Res. 2015; 7:841–855.
145. Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper 
JT, Lentz SS, Hoffman JS, Shahin MS. A phase II evaluation 
of nanoparticle, albumin-bound (nab) paclitaxel in the 
treatment of recurrent or persistent platinum-resistant ovarian, 
fallopian tube, or primary peritoneal cancer: a Gynecologic 
Oncology Group study. Gynecol Oncol. 2011; 122:111–115.
146. Teneriello MG, Tseng PC, Crozier M, Encarnacion 
C, Hancock K, Messing MJ, Boehm KA, Williams 
A, Asmar L. Phase II evaluation of nanoparticle albumin-
bound paclitaxel in platinum-sensitive patients with 
recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin 
Oncol. 2009; 27:1426–1431.
147. Williamson SK, Johnson GA, Maulhardt HA, Moore 
KM, McMeekin DS, Schulz TK, Reed GA, Roby 
KF, Mackay CB, Smith HJ, Weir SJ, Wick JA, Markman 
M, et al. A phase I study of intraperitoneal nanoparticulate 
paclitaxel (Nanotax®) in patients with peritoneal 
malignancies. Cancer Chemother Pharmacol. 2015; 
75:1075–1087.
Oncotarget78224www.impactjournals.com/oncotarget
148. Pinto A, Eveno C, Pocard M. Update on clinical trials in 
colorectal cancer peritoneal metastasis. Int J Hyperthermia. 
2017:1–16.
149. Kepenekian V, Elias D, Passot G, Mery E, Goere D, 
Delroeux D, Quenet F, Ferron G, Pezet D, Guilloit JM, 
Meeus P, Pocard M, Bereder J, et al. French Network 
for Rare Peritoneal Malignancies (RENAPE). Diffuse 
malignant peritoneal mesothelioma: Evaluation of systemic 
chemotherapy with comprehensive treatment through the 
RENAPE Database: Multi-Institutional Retrospective 
Study. Eur J Cancer. 2016; 65:69–79.
150. Cortes-Guiral D, Elias D, Cascales-Campos PA, Badía 
Yébenes A, Guijo Castellano I, León Carbonero AI, 
Martín Valadés JI, Garcia-Foncillas J, Garcia-Olmo D. 
Second-look surgery plus hyperthermic intraperitoneal 
chemotherapy for patients with colorectal cancer at high 
risk of peritoneal carcinomatosis: Does it really save lives? 
World J Gastroenterol. 2017; 23:377–381.
151. Ashvin R, Nikhilesh J. Preoperative Preparation and Patient 
Selection for Cytoreductive Surgery and HIPEC. Indian J 
Surg Oncol. 2016; 7:208–214.
152. Boutros C, Somasundar P, Espat NJ. Early results on the 
use of biomaterials as adjuvant to abdominal wall closure 
following cytoreduction and hyperthermic intraperitoneal 
chemotherapy. World J Surg Oncol. 2010; 8:72.
153. Chia CS, You B, Decullier E, Vaudoyer D, Lorimier G, 
Abboud K, Bereder JM, Arvieux C, Boschetti G, 
Glehen O; BIG RENAPE Group. Patients with Peritoneal 
Carcinomatosis from Gastric Cancer Treated with 
Cytoreductive Surgery and Hyperthermic Intraperitoneal 
Chemotherapy: Is Cure a Possibility? Ann Surg Oncol. 
2016; 23:1971–1979.
154. Liu L, Zhang N, Min J, Su H, Wang H, Chen D, Sun L, 
Zhang H, Li W, Zhang H. Retrospective analysis on the 
safety of 5,759 times of bedside hyperthermic intra-
peritoneal or intra-pleural chemotherapy (HIPEC). 
Oncotarget. 2016; 7:21570–21578. https://doi.org/10.18632/
oncotarget.7622.
155. Kitayama J. Intraperitoneal chemotherapy against peritoneal 
carcinomatosis: current status and future perspective. Surg 
Oncol. 2014; 23:99–106.
